BACKGROUND: To evaluate the effects of vaginal misoprostol on cervical dilatation before operative hysteroscopy in pre-menopausal women. METHODS: Four groups of 12 women were randomly assigned to receive either placebo or vaginal misoprostol in doses of 200, 400 or 800 mg 4 h before the surgical procedure. The number of patients was calculated with an a = 0.01 and b =0.20 for a difference of 50%. The primary outcome measure was cervical width, assessed by the largest size of Hegar dilator that could be inserted without resistance. The secondary outcomes were subjective assessments of the ease of dilatation and pre-operative pain, as well as adverse effects and complications. RESULTS: There was no difference in the baseline diameter of the cervical opening between the placebo group (6.1 T T 1.4 cm) and the misoprostol groups (6.3 T T 2.1 cm). The groups did not differ signi®cantly in the time required for dilatation, ease of dilation, or the number of adverse effects. Pre-operative pain, evaluated by a pain scale, was greater in the treatment groups and was rated at 2.5 T T 2.3 (P = 0.015), 2.4 T T 1.2 (P = 0.073) and 2.8 T T 2.9 (P = 0.012) respectively for each increasing dose group. CONCLUSIONS: Vaginal misoprostol applied 4 h before operative hysteroscopy at three different doses did not reduce the need for cervical dilatation, did not facilitate hysteroscopic surgery, and increased pre-operative pain.
Introduction
Operative hysteroscopy is an important tool for the management of intrauterine abnormalities. Complications encountered during the procedure are partly related to dif®culties in cervical dilatation. These include cervical tears, creation of a false track, haemorrhaging, uterine perforation requiring laparoscopy, or simply dif®culty in entering the internal cervical os with the resectoscope (Loffer et al., 1989; Cooper et al., 1996) . The incidence of these complications can be reduced if the cervix is ripened before the procedure by inserting laminaria into the cervical canal the night before surgery (Ostrzenski, 1994) or by using Sulprostone gel (Rath et al., 1985) .
Misoprostol, a synthetic prostaglandin E 1 analogue widely prescribed for prevention and treatment of gastric ulcers, has been shown to have cervical ripening effects in both pregnant and non-pregnant patients when administered either orally or vaginally (Ngai et al., 1997; Preutthipan et al., 2000) . The systemic bioavailability of misoprostol is three times greater when it is administered vaginally than orally (Zieman et al., 1997) and suggests that vaginal administration could be dosed at longer intervals than oral. The purpose of this randomized, placebo-controlled study was to evaluate the effectiveness of vaginal misoprostol in facilitating cervical dilatation in nonmenopausal women before operative hysteroscopy and to identify the best dose.
Materials and methods
Between January 1 and March 30, 2001, 48 of 56 women (eight patients refused to participate) of reproductive age who required operative hysteroscopy for submucous myoma (n = 36) or polyps (n = 12) were randomly allocated by a computer-generated randomization table to receive either four placebo tablets or three placebo tablets and 200 mg misoprostol or two placebo tablets and 400 or 800 mg misoprostol (Cytotec â ; Laboratories Searle, France), given vaginally 4 h before surgery. The placebo tablets were identical to misoprostol in appearance. Four hours before the procedure, the dry tablets were placed by a nurse in the posterior vaginal fornix.
Surgeons and operating theatre nurses who removed the tablets which were not totally disintegrated after 4 h were blinded to patient allocation. The study was approved by the institutional review board before it began. The study was set in one centre.
Patients who were considered medically ®t were scheduled for operative hysteroscopy under general anaesthesia with a 10 mm hysteroscope during the follicular phase of their cycles.
The primary outcome measure in this study was cervical width, which was assessed by the subjective force required to enter the cervical os without resistance with successive Hegar dilators from 3±8 mm. Surgery was performed by two investigators (Drs Fernandez or Chauveaud-Lambling) to reduce individual variability. Secondary outcome measurements included the subjective ease of cervical dilatation, the time required for dilatation up to Hegar 10, preoperative pain, and the adverse effects and complications of the procedure (cervical injuries, uterine perforation, false track, bleeding). Pain tolerance evaluated by a visual analogue scale (VAS) and sideeffects were noted by the surgical nurses before the procedure.
The exclusion criteria were: contraindication to prostaglandins (asthma, glaucoma, hypertension), history of cervical surgery or of cervical incompetence, and treatment with GnRH agonists.
Sample size was calculated with a test that had an a of 0.01 and a b of 0.20. The study had the power to detect a 50% difference between the treatment and control groups, as shown by Preutthipan et al. (1999) .
Statistical analysis
Results are presented as the mean T SD (range) for quantitative variables and frequency (percentage) for qualitative variables. Analysis of the trial was performed according to the intention-totreat principle and the patients' number was calculated to ®nd a difference in the ef®cacy of the treatment. Groups were compared at inclusion with the Kruskal±Wallis test. For the principal and secondary endpoints, each treatment group was compared with the placebo group. Experimental groups that differed signi®cantly from the placebo group were also compared with one another. Wilcoxon rank sum tests were used for the quantitative variables, since the distribution of the variables was obviously not Gaussian. Fisher's exact tests were used for qualitative variables.
To take multiple testing into account in the assessment of the subjective outcome criteria, the signi®cance level was set at 0.01. For the other global group comparisons, the signi®cance level was P < 0.05.
All analyses were performed with S-Plus 2000 software (MathSoft Inc., USA).
Results

Description of the sample
Forty-eight patients were randomized. One patient withdrew her consent during the study and was therefore excluded from this analysis. The¯ow chart is presented in Figure 1 . The time interval between insertion and the operative hysteroscopy was 4 h and 5 min (range: 3 h 50 min to 4 h 20 min).
The study therefore assessed 47 patients divided into four groups: placebo group (n = 13), a group receiving 200 mg misoprostol (n = 12), a group receiving 400 mg of misoprostol (n = 12), and another group receiving 800 mg of misoprostol (n = 10).
All inclusion and exclusion criteria in the study were met. Nonetheless one patient had to withdraw from the study because she was found during surgery to be pregnant. The data for this patient were included in the analysis, in compliance with the principle of intention-to-treat analysis. Similarly, one patient received a different treatment than that to which she was randomly allocated. Indeed, she received placebo tablets instead of 800 mg of misoprostol. So, the analysis considered her to be in the group to which she was allocated, that is, group 1 (Table I) .
Analysis of the outcome measures
At a risk a=1%, the results reported in Table II and Table III do not enable us to conclude that misoprostol had any effect on spontaneous cervical dilatation at any dose (Figure 3 ). Nor do they allow us to judge the ef®cacy of the treatment or the effect on the duration of dilatation (Figure 2) . Similarly, it is not possible to conclude that the treatment made any difference in terms of the nature of the dilatation or complications. On the other hand, pre-operative pain increased with the use of misoprostol (Figure 4 ).
Discussion
We administered misoprostol vaginally at three different doses 4 h before operative hysteroscopy and compared the results with placebo: misoprostol was not associated signi®cantly with better baseline cervical opening, it did not decrease the time to cervical dilatation, or affect the degree of dif®culty in dilatating the cervix regardless of dose. However, in the placebo group, we observed two dif®cult dilatations (2/13) against three among 34 patients treated by misoprostol whatever the dose regimen. In addition, misoprostol was associated with more pre-operative pain. In this study, we evaluated only subjectively the force required to enter the cervical os. Ngai (1999) used a force-sensing handle and baseline dilatation was de®ned as the ®rst dilator requiring a peak force of 5 N and the cumulative force was calculated by adding the peak forces needed for each dilator up to 8 mm.
Obviously, this objective evaluation would be better but this cervical tonometer was not available in our centre. However, we would like initially to evaluate the surgeon's reaction in intention-to-treat.
To limit the bias due to dilatation, we excluded menopausal women and the women treated with GnRH agonists and we always operated during the follicular phase. Cooper et al. (1996) showed that the lack of estrogen induced by agonists may explain the inef®cacy of misoprostol.
The route of administration and the delay separating misoprostol administration from the surgery were justi®ed by the study on misoprostol absorption kinetics (Zieman et al., 1997) . The comparative analysis of the serum levels of the principal metabolite of misoprostol revealed that bioavailability was best following vaginal administration (T max = 80 T 27 min), followed by a plateau phase lasting several hours. Moreover, since all our patients underwent outpatient surgery, this facilitated the organization of the study and seemed to ensure that we were in compliance with prescriptions and could monitor possible side-effects during hospitalization.
The lack of ef®cacy of misoprostol, at three successive doses, may therefore be related to the time period separating its administration (vaginal or oral) from the surgery. Indeed, in our series the tablets were never disintegrated totally at the time of surgery. Thomas et al. (2002) and Preutthipan et al. (1999) reported in larger series that administration respectively of 400 mg oral misoprostol 12 or 24 h before surgery or 200 mg vaginal misoprostol 9±10 h before surgery demonstrated an increased ease of cervical dilatation, but at the price of mild side-effects such as diarrhoea, cramps and vaginal bleeding, which were reported in an average of 25% of cases.
Nonetheless, no placebo-controlled trials so far have shown a signi®cant diminution in the rate of severe complications such as cervical laceration or perforation. Does the surgeon's subjective assessment that dilatation is facilitated, when combined with a side-effect rate of 25%, justify the prescription of misoprostol before operative hysteroscopy? We must answer that no bene®t was demonstrated when misoprostol is given 4 h before the intervention, since our study con®rmed the inef®cacy of this protocol. Twelve hours earlier, that is, at home, the night before the procedure, without the ability to treat the side-effects, the answer could be positive, but the risk:bene®t ratio needs more thorough assessment. The sublingual administration of 100 mg of misoprostol 12 h before surgery is not ef®cacious (Bisharah et al., 2003) , even though Tang et al. (2002) found a peak of high concentration after sublingual administration.
In conclusion, administration of misoprostol up to 800 mg 4 h before operative hysteroscopy showed no evidence of promoting cervical dilatation. Other studies assessing the ef®cacy and optimizing the dose of misoprostol are necessary to learn whether there is any real effect of this product on the cervix or only the surgeon's subjective assessment.
